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Abstract
Hypogonadotropic hypogonadism (HH) is characterised by delayed puberty and infertility. Congenital HH comprises Kallmann syndrome 
with hypo-/anosmia and idiopathic HH (IHH). The genetic origin remains unknown in most cases, but the defective GnRH receptor gene 
(GNRHR) accounts for a considerable proportion of IHH. 
Here we describe a pair of siblings diagnosed with IHH. Aged 17 years, the boy was referred because of short stature (162 cm) and over-
weight (62.5 kg). He presented no signs of puberty, bone age of 14.5 years and insulin resistance. His sister, aged 16 years, also displayed 
delayed puberty. She was 166 cm tall and weighed 52 kg; her bone age was 12.5 years. Pelvic ultrasonography showed an infantile uterus 
and fibrous ovaries. In both siblings, serum gonadotropins were extremely low, and non-responsive to GnRH. Testosterone (1.38 nmol/l) 
and IGF1 (273 ng/ml) were decreased in the boy, although the girl did not present IFG1 deficiency. Her serum oestradiol was 10 pg/ml. 
MRIs of the hypothalamo-pituitary region and olfactory bulbs revealed them to be normal. The patients’ sense of smell was unaltered. 
Their parents appeared to be first degree cousins. Considering the clinical data and potentially autosomal recessive HH transmission, the 
GNRHR gene was screened. The siblings turned out to be homozygous for the G416A transition, which had previously been identified 
in other HH individuals. The parents were heterozygous mutation carriers. The proband, moderately responding to LH, was started on 
low dose testosterone replacement, and his sister on transdermal oestradiol. Molecular data indicative of GnRH resistance could guide 
their future therapy should they desire fertility restoration. Further observations of the male patient may provide insights into androgen’s 
influence on body mass, growth and insulin sensitivity. 
(Pol J Endocrinol 2011; 62 (3): 264–267)
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Streszczenie
Hipogonadyzm hipogonadotropowy (HH) charakteryzuje się opóźnionym dojrzewaniem i bezpłodnością. Wrodzony HH obejmuje zespół 
Kallamana z hipo-/anosmią oraz przypadki idiopatyczne (IHH). Podłoże genetyczne choroby pozostaje zazwyczaj niejasne, choć defekty 
genu receptora dla GnRH (GNRHR) odpowiadają za istotną część przypadków.
W pracy zaprezentowano opis pary rodzeństwa z rozpoznanym IHH. W wieku 17 lat u chłopca przeprowadzono konsultację z powodu 
niskorosłości (162 cm) i nadwagi (62,5 kg). Badania wykazały brak dojrzewania płciowego, wiek kostny oceniono na 14,5 roku oraz stwier-
dzono insulinooporność. U 16-letniej siostry również występowało opóźnione dojrzewanie. Chora miała 166 cm wzrostu, ważyła 52 kg; 
wiek kostny oceniono na 12,5 roku. Badanie ultrasonograficzne wykazało obecność dziecięcej macicy i włóknistych struktur jajników. 
U obojga rodzeństwa stwierdzono niskie stężenia gonadotropin w surowicy, bez reakcji na GnRH. Stężenie testosteronu (1,38 nmol/l) 
oraz IGF1 (273 ng/ml) były obniżone u chłopca, podczas gdy u dziewczynki nie wykazano niedoboru IGF1. Stężenie estradiolu w jej 
surowicy wynosiło 10 pg/ml. U obojga rezonans magnetyczny nie wykazał patologii okolicy podwzgórzowo-przysadkowej ani opuszek 
węchowych. Poczucie węchu nie było zaburzone. 
Rodzice dzieci okazali się kuzynostwem pierwszego stopnia. Biorąc pod uwagę dane kliniczne oraz prawdopodobne autosomalne rece-
sywne dziedziczenie HH, do badań molekularnych wybrano gen GNRHR. U rodzeństwa wykryto homozygotyczną tranzycję G416A, 
wcześniej opisywaną u innych chorych. U rodziców wykazano heterozygotyczne nosicielstwo mutacji. U probanda, wobec słabej reakcji 
na LH, włączono substytucję niskimi dawkami testosteronu, a u jego siostry — przezskórny preparat estradiolu. Z uwagi na oporność na 
GnRH wyniki badań molekularnych mogą wspomóc przyszłe decyzje terapeutyczne w przypadku prób indukcji gametogenezy. Dalsza 
obserwacja chłopca może dostarczyć danych na temat wpływu androgenów na skład masy ciała, wzrastanie oraz insulinowrażliwość.
(Endokrynol Pol 2011; 62 (3): 264–267)
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Hypogonadotropic hypogonadism (HH) is characte- 
rised by delayed or absent puberty and infertility. Go-
nads, deficient in gonadotropic stimulation, fail to un-
dertake their hormonal and gametogenic function. HH 
may be due to acquired local lesions (tumour, trauma, 
infiltrative disorders, etc.) but can also arise from genetic 
defects that impair the development and/or function of 
the hypothalamo-pituitary region [1]. 
Congenital HH is a heterogenous condition, tradi-
tionally subdivided into Kallmannsyndrome associated 
with hypo-/anosmia, and idiopathic HH (IHH) which 
is diagnosed in patients without olfactory deficit [2]. 
Mutations in several genes have been identified 
in HH, although in the majority of cases the genetic 
background remains unknown. The genes responsible 
for Kallmann syndrome comprise KAL1, FGF8, FGFR1, 
PROK2 and PROKR2, all involved in GnRH neurons 
migration during ontogenesis [3]. On the other hand, 
mutations leading to IHH have mostly been found 
in genes which are critical from the functional point 
of view [2, 4]. Precise pulsatile GnRH secretion is re-
quired for gonadal steroidogenesis and gametogenic 
function. Despite several attempts, it was only recently 
that a unique loss-of-function mutation (1-bp insertion 
18insA) in the gonadotropin-releasing hormone gene 
(GNRH1) was found in a Romanian sibling with IHH [5]. 
Considering the rarity of GNRH1 mutations, defective 
GnRH receptor was another logical candidate for IHH 
[6]. In fact, GNRHR mutations may account for up to 
40% of familial, and 16.7% of sporadic, cases of normos-
mic HH [7]. Other genes recently associated with IHH 
include GPR54/KISS1R, TAC3 and TACR3, which may 
all affect GnRH secretion [3, 4].
Case report
Here we describe a pair of siblings diagnosed with iso-
lated hypogonadotropic hypogonadism. A boy and a girl 
were born at term to a consanguineous couple, following 
two uncomplicated pregnancies. They reached all mo-
tor milestones at the correct time, and their intellectual 
development was normal. A gradual decrease in growth 
velocity and increasing body mass were observed in the 
boy, starting approximately at the age of 11. Aged 17, 
he was referred to the endocrine department because 
of shortness (162 cm; < 3rd percentile) and overweight 
(62.5 kg, 25–50th percentile, BMI = 23.8 kg/m2, Cole In-
dex = 112%). Physical examination revealed no signs 
of pubertal development, a prepubertal penile size and 
small intrascrotal testes (1.5 ml each) without pathology 
on ultrasound. The patient’s bone age was 14.5 years 
— his adjusted height was at the 25th percentile while 
Cole Index reached 121%. Serum gonadotropins were 
extremely low and did not respond to GnRH stimula-
tion (Table I). Serum testosterone level was decreased 
(1.38 nmol/l) while TSH, free thyroxin, prolactin, ACTH, 
cortisol and DHEA-S were all within their normal rang-
es. IGF1 in his serum (273 ng/ml) was at the 20th percentile 
for chronological and bone age. His sense of smell was 
unaltered. MRI evaluation of the hypothalamo-pituitary 
region did not reveal any structural pathology and no 
abnormalities of the olfactory bulbs were noticed. An oral 
glucose tolerance test (OGTT) was performed, indicat-
ing impaired glucose tolerance (glucose rise from 93 to 
173 mg/dl) with concomitant insulin resistance (insulin 
increase from 21.0 to 258.3 μIU/ml) [8]. 
Diagnosed with IHH, the patient was prescribed 
a 12-week course of hCG (Pregnyl 1500 IU i.m. thrice 
per week) and responded with a testosterone rise 
up to 5.86 nmol/l. One month after Pregnyl cessa-
tion, his testosterone was found to be low again 
(2.27 nmo/l), IGF1 was 309 ng/ml and Tanner ’s stage 
had not progressed except for the mild stage 2 of 
pubarche. Substitution therapy with a mixture of 
testosterone esters (Omnadren 250) was introduced, 
starting at 50 mg i.m. every four weeks. A balanced, 
calorie-restricted diet and regular physical exercise 
were advised in order to decrease his body mass and 
improve insulin sensitivity. 
Additionally, it turned out that his younger sister, 
aged 16, also displayed delayed puberty (lack of me-
narche, thelarche 1, axillarche 2, pubarche 1 Tanner’s 
Table I. Results of the GnRH stimulation test in the affected sibling
0’ 30’ 60’ 90’
Male patient (17-years-old)
   LH [mIU/ml] 0 0 0 0
   FSH [mIU/ml] 0.4 0.4 0.5 0.3
Female patient (16-years-old)
   LH [mIU/ml] 0.1 0.1 0.3 0.3
   FSH [mIU/ml] 0.4 0.4 0.4 0.3
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stage). The girl was 166 cm tall (50–75th percentile) and 
weighed 52 kg (25–50th percentile). Her bone age was 
12.5 years. Pelvic sonography revealed an infantile uterus 
(1.5 cm length with 1mm endometrial layer) and two 
fibrous ovaries, without visible follicles. The girl did not 
present any olfactory deficit, nor any pathologies on her 
head MRI. Similarly to her brother, serum LH and FSH 
concentrations were extremely low, and non-reactive 
to exogenous GnRH (Table I). Serum oestradiol was 
decreased (10 pg/ml); testosterone and androstenedione 
were 0.65 nmol/l and 1.3 ng/ml, respectively. TSH, free 
thyroxin, prolactin, ACTH, cortisol and DHEA-S were 
all within their reference ranges. Her serum IGF1 (593 
ng/ml) was at the 80–95th percentile for both chronologi-
cal and bone age. The girl did not display disorders in 
glucose-insulin homeostasis as assessed by OGTT. Low 
dose (25–37.5 mcg/24 h) transdermal oestradiol substitu-
tion was introduced. Progress in breast development and 
vaginal mucus discharge were noted two months later.
The healthy parents of the affected adolescents ap-
peared to be first degree cousins. This finding raised 
a suspicion of autosomal recessive mode of inheritance 
of HH. The parents and children consented to further 
molecular analyses. Genomic DNA was extracted from 
peripheral blood cells. Considering the clinical data, i.e. 
normosmic HH with no other congenital defects and 
potential autosomal recessive transmission, priority was 
given to the gene encoding GnRH receptor (GNRHR). 
All three exons were amplified by polymerase chain 
reactions with three sets of intronic primers (details 
available upon request). Products were purified and 
sequenced bi-directionally using BigDye terminator 
cycle sequencing ready reaction kit on an ABI PRISM 
automatic sequencer. Sequences obtained were aligned 
with the Genebank reference NC_000004.11. The sib-
lings were found to be homozygous for the G>A transi-
tion at position 416 within exon 1 of the GNRHR gene 
(Figure 1). This nucleotide change results in substitution 
of arginine for histidine at codon 139 (R139H) within the 
conserved DRS amino acid motif. Molecular screening 
of the parents revealed that both of them were hetero-
zygous carriers of the same mutation, which confirmed 
the suspected mode of inheritance of the disease.
Discussion
The human GNRHR gene is located on chromosome 
4q21.2 and encodes a 328-amino acid membrane protein 
[9]. To date, 27 GNRHR mutations, which confer complete 
or partial GnRH resistance, have been found in patients 
with IHH. Various mutations may affect the receptor 
expression, ligand binding affinity or signal transduction, 
and therefore account for the different degrees of HH 
observed among patients [10]. The homozygous R139H 
GNRHR mutation was previously identified in a Brazil-
ian female who presented with primary amenorrhea, 
lack of breast development at 18 years, and low serum 
gonadotropins, unresponsive to exogenous GnRH [11]. 
An unrelated male of Polish origin with a homozygous 
R139H mutation was subsequently described [12]. Aged 
19, he lacked any features of puberty and functional 
assessment of his hypothalamo-pituitary-gonadal axis 
confirmed complete HH [12]. The cardinal role of the 
highly conserved arginine residue was further supported 
by the finding of another substitution at this site, R139C, 
in two Turkish sisters with IHH [13].
In vitro studies revealed that cells transfected with 
mutant 139H GNRHR cDNA displayed normal ex-
pression and membrane localisation of GnRH recep-
tors. However, they were unable to respond properly 
to GnRH, apparently due to abolished ligand binding 
and subsequent lack of intracellular signal transduction 
[11]. The GnRH receptor belongs to the family of the 
rhodopsin-like G protein-coupled receptors, composed 
of seven transmembrane domains and an extracellular 
amino-terminus [9]. Its activation results in increased 
Figure 1. Results of the GNRHR gene sequencing in the studied family
Rycina 1. Wyniki sekwencjonowania genu GNRHR u członków badanej rodziny
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activity of the phospholipase C and mobilisation of intra-
cellular calcium stores [14]. The R139H mutation occurs 
within the conserved DRS motif at the junction of the 
third transmembrane domain and the second intracel-
lular loop. It seems that protonation of the R139 residue, 
and its interaction with the neighbouring D138, are 
critical in maintaining active receptor conformation [15].
The results of mutational analysis did not substan-
tially influence sex steroid replacement, which was 
instituted in both adolescents in order to achieve and 
maintain mature secondary sexual characteristics [16]. 
Nonetheless, it may provide useful hints if fertility 
restoration is desired. Due to the recessive inheritance 
pattern, patients with GNRHR mutations are unlikely to 
transmit the disease to their offspring, therefore fertility 
issues become of major concern. Most studies compar-
ing pulsatile GnRH and hCG/hMG protocols in induc-
ing gametogenesis among HH patients have revealed 
both approaches to be similarly effective [17]. However, 
in various cohorts, there are always individuals who fail 
to respond to this form of therapy. Molecular analysis 
might provide an explanation as to why some of these 
patients could be carriers of GNRHR mutations, result-
ing in complete GnRH resistance. On the other hand, 
cases of successful conception after high-dose GnRH 
pulsatile therapy have also been reported in subjects 
with milder receptor impairment, although pregnancy 
maintenance required repeated GnRH support [18]. 
Overall, gonadotropin stimulation seems more likely 
to induce ovulation/spermatogenesis in patients with 
GNRHR defects [18, 19].
By contrast, the phenotypic differences found in the 
studied sibling require further investigation. Siblings 
partially share a genetic background as well as most 
exogenous factors of the environment where they are 
brought up. Moreover, it is generally recognised that 
hypogonadism promotes increased body fat mass and 
insulin resistance in both genders. However, only the 
boy presented short stature and overweight compli-
cated by insulin resistance. Impaired linear growth 
may also result from lack of pubertal androgens [20]. 
In healthy boys, the peak rise in testosterone levels (at 
G3/4 Tanner stage) coincides with an increase in mean 
24 h hGH serum concentration and correlates with the 
pubertal growth spurt [21]. According to several studies, 
testosterone replacement therapy tends to improve in-
sulin sensitivity and ameliorate body mass composition 
in males with IHH [22]. These parameters will require 
careful evaluation during follow-up of our patient.
Conclusion
Molecular analysis has enabled us to elucidate the aetiol-
ogy of IHH in the studied siblings and, to some extent, 
may inform their future fertility treatment. Further 
observation of the male sibling may provide interesting 
insights into androgen’s influence on body stature and 
insulin sensitivity in adolescents. 
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